Generic Drug Pricing

In Massachusetts the cost of prescription drugs is rising at 13%, or three times the rate of overall healthcare according to the Boston Globe.  Generic drugs represent 8 in 10 prescriptions filled in the US and the FDA expects to see an upward trend.  It stands to reason that the cost of generic drugs is going to be an increasingly important component of self-funded insurance.  Let’s take a look at what’s driving generic drug pricing and what to expect in the coming years.

There are a few generally accepted forces behind the increase in generic drug pricing.  The following is an overview of five forces affecting generic drug pricing from a paper written by the National Center for Policy Analysis.

Oligopolistic pricing.

Mergers of the current pharmaceutical companies have reduced the overall number of drug makers to only a handful.  Since there are so few drug makers it’s easy to keep tabs on competitors’ pricing.  With demand high for generics, why lower your prices when you can raise them?  Specific instances of pricing spikes have hit the news recently drawing attention to this issue.

Drug wholesalers.

Not only are there not many drug makers, three companies generate about 85% to 90% of all revenues from drug distribution in the US.  With this much power, drug wholesalers have tremendous influence on drug prices paid by the end consumer.

No/few new entrants.

With all of this money to be made, one might think this is an appealing industry for new companies to enter the market. However, drug manufacturing is subject to FDA approval so new entrants into the market must be approved, a process that can take a long time with high upfront costs that deter companies from trying.

Raw material shortages.

Not all price increases are due to business practices.  In 10% of cases, a lack of raw materials is to blame for higher prices or a shortfall of available drugs to meet the demand of the market.  80% of raw materials are sourced internationally so political and environmental forces are sometimes at play.

FDA Drug Approval time.

In 2010, the median approval time for new generic drugs by the FDA was more than two years (27 months).  This is nearly double the time it took five years early (16 months in 2005).

As you can see, it has been a sellers’ market and insurance companies and self-funded plans have had to deal with increasing costs.  To share the burden, many plans now asking patients to pick up more of the cost for prescription drugs through higher copayments and tiered pricing systems that encourage the selection of lower cost options.  Additionally, plans may need to increase the plan rates since the additional cost for generic drugs is driving the total cost of claims higher.

If you have questions about this topic or your stop loss insurance policy, please contact us.  




Contact Block (Blog)

Recent Comments

    Newsletter Signup

    Signup to start receiving the latest newsletters from StopLoss right to your email.
    Stay up to date on insurance trends and insights.

    Back to Top

    In 2011, the top 5 most expensive medical conditions treated in US hospitals were: Septicemia, Osteoarthritis, Complication of device, implant or graft, Liveborn, and Acute myocardial infarction

    From 2010 to 2013, the number of claims that were individually $1 million or above rose by 1,000%

    In 2017 approximately 18% of the American public will purchase insurance through exchanges, radically transforming the health insurance landscape.

    In 2014, 98% of large firms (= 200 Workers) offer 1+ wellness programs to their employees.

    The most costly 1% of patients account for 20% of national health expenditures – accruing average annual expenses of nearly $90,000 per person.

    6% of firms offering fully-insured plans report they intend to self-insure because of Obamacare.

    In 2014, PPO plans remained the most common plan type, enrolling 58% of covered workers.

    In 2012, 93% of businesses with 5,000+ employees and 80% of companies with 1,000-4,999 employees were self-funded

    Massachusetts has the third-highest prevalence of self-funded insurance in the small-group market (Fewer than 50 employees).

    In 2013, the average deductible was $2,906 for individuals selecting plans from marketplaces. This compares with average deductibles of $1,135 for an individual with employer coverage.

    In 2013, the average annual premiums for employer-sponsored health insurance are $5,884 for single coverage and $16,351 for family coverage, up 5% and 4% respectively from 2012.

    From 2010 – 2013, cancer followed by chronic/end stage renal disease and leukemia accounted for the top 3 costliest illnesses.